

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61L 33/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/08553</b> <b>(43) International Publication Date:</b> 5 March 1998 (05.03.98)
<b>(21) International Application Number:</b> PCT/US96/14274 <b>(22) International Filing Date:</b> 29 August 1996 (29.08.96)  <b>(71) Applicant:</b> MEDTRONIC, INC. [US/US]; 7000 Central Avenue Northeast, Mail Stop 301, Minneapolis, MN 55432 (US).  <b>(72) Inventors:</b> VERHOEVEN, Michel; Parallelweg 39, NL-6221 BD Maastricht (NL). CAHALAN, Linda, L.; Elegastraat 10, NL-6166 KE Geleen (NL). HENDRIKS, Marc; Raambouwstraat 118, NL-6432 RV Hoensbroek (NL). FOUACHE, Benedicte; Achter de Molens 7, NL-6211 JC Maastricht (NL). CAHALAN, Patrick, T.; Elegastraat 10, NL-6166 KE Geleen (NL).  <b>(74) Agents:</b> LATHAM, Daniel, W. et al.; Medtronic, Inc., 7000 Central Avenue Northeast, Mail Stop 301, Minneapolis, MN 55432 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> BIOCOMPATIBILITY FOR SOLID SURFACES  <b>(57) Abstract</b> <p>An improved coating and spacer material for a medical device having a blood or tissue-contacting surface comprising a polyalkyleneimine layer which is cross-linked with a cross-linking agent which is at least difunctional in polymerizable vinyl groups which have adjacent strong electron-withdrawing groups and a biomolecule covalently bonded to the cross-linked polyalkyleneimine layer. For example, polyethyleneimine cross-linked with divinyl sulfone could be used. The resulting cross-linked spacer layer has improved uniformity and stability without materially limiting the covalent attachment of a biomolecule such as heparin.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NR	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## BIOCOMPATABILITY FOR SOLID SURFACES

### BACKGROUND OF THE INVENTION

This invention relates to the enhancement of the biocompatibility of various surfaces of medical devices by binding biomolecules such as heparin to the surface. Medical devices which serve as substitute blood vessels, synthetic and intraocular lenses, electrodes, catheters and the like in and on the body or as extracorporeal devices intended to be connected to the body to assist in surgery or dialysis are well known. However, the use of such biomaterials in medical devices can stimulate adverse body responses, including rapid thrombogenic action. Various plasma proteins play a role in initiating platelet and fibrin deposition on plastic surfaces. These actions lead to vascular constriction to hinder blood flow, and the inflammatory reaction that follows can lead to the loss of function of the medical device.

A "biomaterial" may be defined as a material that is substantially insoluble in body fluids and that is designed and constructed to be placed in or onto the body or to contact fluid of the body. Ideally, a biomaterial will not induce undesirable reactions in the body such as blood clotting, tissue death, tumor formation, allergic reaction, foreign body reaction (rejection) or inflammatory reaction; will have the physical properties such as strength, elasticity, permeability and flexibility required to function for the intended purpose; can be purified, fabricated and sterilized easily; will substantially maintain its physical properties and function during the time that it remains implanted in or in contact with the body.

As used herein, the solid surface of a biomaterial is characterized as "biocompatible" if it is capable of functioning or existing in contact with biological fluid and/or tissue of a living organism with a net beneficial effect on the living organism. Long term biocompatibility is desired for the purpose of reducing disturbance of the host organism. One approach to improved biocompatibility for biomaterials is to attach various "biomolecules" which can promote the thromboresistance of the device.

Immobilization of polysaccharides such as heparin to biomaterials has been researched extensively to improve bio- and hemocompatibility.

The mechanism responsible for reduced thrombogenicity of heparinized materials is believed to reside in the ability of heparin to speed up the inactivation of serine proteases (blood coagulation enzymes) by AT-III. In the process, AT-III forms a complex with a well defined pentasaccharide sequence in heparin, undergoing a conformational change and thus enhancing the ability of AT-III to form a covalent bond with the active sites of serine proteases such as thrombin. The formed TAT-complex then releases from the polysaccharide, leaving the heparin molecule behind for a second round of inactivation.

Usually, covalent immobilization of heparin to a biomaterial consists of activating the material in such a way that coupling between the biomaterial and functional groups on the heparin (-COOH, -OH, -NH<sub>2</sub>) can be achieved. Thromboresistant surfaces are not necessarily obtained using these processes. Heparin can be bound too tightly to the surface due to the high abundance of functional groups on the heparin, or coupling may result from bonds between the active pentasaccharide sequence on the heparin and the biomaterial, preventing activation of AT-III and thus catalytic deactivation of the proteases. In order to obtain truly anti-thrombogenic surfaces, proper immobilization of the biomolecules is key. Larm presented (in U.S. Patent 4,613,665) a method to activate heparin via a controlled nitrous acid degradation step, resulting in degraded heparin molecules of which a part contains a free terminal aldehyde group. Heparin in this form can be covalently bound to an aminated surface in a reductive amination process.

Although the molecule is degraded and as a result shows less catalytic activity in solution, the end point attachment of this type of heparin to a surface results in true anti-thrombogenicity due to the proper presentation of the biomolecule to the surface. In this fashion, the molecule is freely interacting with AT-III and the coagulation enzymes, preventing the generation of thrombi and microemboli.

Besides the coupling of heparin via its natural functional groups or through a terminal aldehyde group, coupling of heparin via aldehyde groups randomly introduced into the chain by means of periodate oxidation has also been described. Solomon et al (in U.S. Patents 4,600,652 and 4,642,242) and Hu et al (in U.S. Patents 4,720,512;

4,786,556; 5,032,666 and 5,077,372) coupled heparin after periodate oxidation to an aminated polyurethane obtaining a material with high loading of stably bound heparin.

Spacer molecules have been used to connect heparin and other biomolecules to a substrate. A spacer molecule is a molecule or compound which is capable of attachment to a solid surface, is large enough to extend from the surface of said surface and is capable of immobilizing a biomolecule and/or biomolecules. The spacer insures that the active site of the biomolecule is held outward away from the support so as to contact the body fluid efficiently. The spacers are derived from organic molecules having at least two reactive functional groups generally situated at opposing ends of the molecule. Such groups serve as attachment vehicles capable of coupling the spacer to the solid surface and to the biomolecule. For example, in U.S. Patent 5,132,108 to Narayanan et al., a copolymer surface was subjected to radiofrequency plasma treatment by subjecting it to a radiofrequency electric field in the presence of a water vapor plasma medium. An aqueous solution of polyethyleneimine (PEI) and 1-(3-dimethylpropyl)-3-carbodiimide (EDC) coupling agent was applied to the radiofrequency plasma discharge modified polyurethane surface. An aqueous solution of heparin and EDC was then applied to the PEI-treated surface in order to provide a polymeric surface having an anti-thrombogenic agent secured to its surface. However, the addition of such spacer molecules to implanted medical device surfaces also adds instability to the surfaces and increases the prospect for burial of the attached biomolecule in the spacer layer and also for damage to the surfaces as the device is handled or implanted.

Additional stability can be provided, for example, according to U.S. Patent 4,565,740 to Golander et al. or U.S. Patent 5,049,403 to Larm et al. In the first of these patents, a complex of a polymeric cationic surfactant (e.g. polyethyleneimine) and a dialdehyde (e.g. glutaraldehyde) is adsorbed onto a substrate material. In the second of these patents, a polyamine is adsorbed onto the surface of a substrate and crosslinked with crotonaldehyde. However, glutaraldehyde and crotonaldehyde do not provide a stable crosslink immediately since the bonds formed are of the hydrolytically unstable imine type. As a consequence, relatively high levels of crosslinkers are used

which might cause excessive crosslinking and even precipitation as the crosslinking proceeds. This leads to irregular coating. Furthermore, due to the high level of crosslinker needed to obtain effective crosslinking, the crosslinkers are not used in the top layer of polyamine in order not to compromise the level of primary and secondary amines needed for immobilization of the biomolecule.

It is therefore an object of the invention to provide a medical device surface for the attachment of heparin and other biomolecules with a crosslinked spacer layer of improved uniformity.

It is also an object of the invention to provide a spacer in which the portion of the spacer nearest to the biomolecule is crosslinked and thereby provides a spacer of improved stability.

#### SUMMARY OF THE INVENTION

We have discovered an improved coating and spacer material for a medical device having a blood or tissue-contacting surface and a method for making it comprising a polyalkyleneimine layer which is crosslinked with a crosslinking agent which is at least difunctional in polymerizable vinyl groups which have adjacent strong electron-withdrawing groups and a biomolecule covalently bonded to the crosslinked polyalkyleneimine layer. The polyalkyleneimine can be, for example, polyethyleneimine and the crosslinking agent can be, for example, divinyl sulfone. This spacer material and coating can be made by reacting the polyalkyleneimine with the crosslinking agent, applying the reacted composition to the solid surface and then bonding the biomolecule to the amine functionalities of the crosslinked polyalkyleneimine coating. When the biomolecule is heparin, the heparin can be attached to the amine functionalities by treating the heparin to produce a pendant aldehyde group on the heparin and then bringing the heparin into contact with the crosslinked polyalkyleneimine. The amount of the crosslinking agent used in making the spacer material is small enough to leave an adequate population of amine groups in the spacer material to bond to the biomolecule. For example, when using divinyl sulfone as the crosslinker for polyethyleneimine (i.e. having 12 mmol per gram total amines with a ratio of primary amine:secondary amine:tertiary amine or 1:2:1), only

about 50-1000 mmol of crosslinker should be used per gram of polyethyleneimine with preferably 100-200 mmol of crosslinker used per gram of polyethyleneimine.

Preferably, the crosslinking agent used to crosslink the polyalkyleneimine is reacted with the polyalkyleneimine in dilute aqueous solution and at a suitable pH to accomplish the light crosslinking of the polyalkyleneimine.


#### **DETAILED DESCRIPTION OF INVENTION**

In the present method, a medical device can be provided with a blood or tissue-compatible surface of improved biocompatibility. By medical device, is meant devices which have surfaces which contact blood or tissue of a patient in the course of their operation. This can include, for example, extracorporeal devices for use in surgery such as blood oxygenators, blood pumps, blood sensors, tubing used to carry blood and the like which contact blood which is then returned to the patient. This can also include endoprostheses implanted in blood or tissue contact in a human or animal body such as vascular grafts, stents, pacemaker leads, heart valves and the like which are implanted in blood vessels or in the heart. This can also include devices for temporary intravascular use such as catheters, guide wires and the like which are placed into the blood vessels or the heart for purposes of monitoring or repair.


In the present invention, a polyalkyleneimine reacted with a crosslinking agent which is at least difunctional in vinyl groups is applied to a solid surface and is employed to provide a spacer on the solid surface for the purpose of improving its biocompatibility.

The solid surface that is rendered biocompatible is desirably of a synthetic or natural material that is insoluble in physiological fluids. The surface may be one or more surfaces of devices intended to function in contact with tissue and/or fluids of living organisms. The substrate for this solid surface of the device may be any suitable metal such as titanium, tantalum or stainless steel or a polymer such as polyurethane, polyvinylpyrrolidone, silicone elastomers, polyolefins such as polyethylene or polypropylene, polytetrafluoroethylene, polyvinyl chloride, polyesters, fluoropolymers, polyacrylates (including polymethacrylates); minerals or ceramics such as hydroxyapatite; human or animal tissue such as bone, skin and teeth; organic materials such as wood, cellulose and compressed carbon; and other natural and synthetic materials such as glass, rubber, wood and the like.


The polyamine used in the present invention can be, for example, polyethyleneimine or other branched polyalkyleneimines. By polyalkyleneimine, we mean to include the water soluble, hydrophilic, polyamines evolving from aziridine and azetidine monomers such as 1-unsubstituted imines, 1-substituted basic imines, activated imines (1-acyl substituted imines), isomeric oxazolines/oxazines and the like. The polyalkyleneimines employed in the present invention are preferably highly branched, thereby possessing primary, secondary, and tertiary amine groups. Thus, ethyleneimine polymerized by classical cationic chain-growth polymerization, either alone or with other monomers suitable for copolymerization with ethyleneimine, could be used in the present invention. The crosslinking agent employed in the present invention can be any crosslinking agent which is at least difunctional in vinyl groups and which includes adjacent to each of the vinyl groups strong electron-withdrawing groups which polarize the double bond of the vinyl group and make it susceptible to anionic attack. For example, sulfone, carbonyl, azo, sulfamido and nitro groups are strong electron-withdrawing groups which could be used. Divinyl compounds with adjacent sulfone groups are preferred such as compounds having the structure



where A is selected from the group consisting of



and



where R is a C<sub>1</sub> to C<sub>10</sub> alkyl group. The most preferred crosslinking agent is divinyl sulfone.

The spacer material of the present invention can therefore be made by reacting a polyalkyleneimine with the crosslinking agent and then applying the reacted mixture to the solid surface of the medical device. Preferably, the crosslinking agent used to



crosslink the polyalkyleneimine is applied in dilute solution and in an amount and at a suitable pH to accomplish only light crosslinking and to preserve the amine functionality for the polyalkyleneimine surface that will allow biomolecules to readily bond to the spacer. This requires a stoichiometry for the reaction in which there is a substantial excess of amine groups. For example, when using divinyl sulfone as the crosslinker for polyethyleneimine (i.e. a polyethyleneimine having 12 mmol per gram total amines with a ratio of primary amine:secondary amine:tertiary amine or 1:2:1), only about 50-1000 mmol of crosslinker should be used per gram of polyethyleneimine with preferably 100-200 mmol of crosslinker used per gram of polyethyleneimine. Thus, the amount of crosslinker reacted with the polyalkyleneimine should be limited so that a maximum of about 1/6 of the total amines could be used in the crosslinking reaction. Preferably, less than about 1/30 of the total amines would be used. The reaction between crosslinker and polyalkyleneimine preferably takes place in a dilute aqueous solution. For example, with polyethyleneimine as the polyalkyleneimine a concentration of polyethyleneimine of about 0.05 wt% could be used. Also, for example, a pH for the reaction solution in the range of about 7 to about 10 would be preferred for polyethyleneimine and divinyl sulfone. Since the reaction is limited by the relative stoichiometric excess of amine groups, no precise reaction time is required. The reaction between polyethyleneimine and divinyl sulfone in dilute solution can be allowed to proceed to completion at room temperature overnight.

The crosslinked polyalkyleneimine is preferably strongly bonded to the solid surface, for example, by covalently attaching the crosslinked polyalkyleneimine to the solid surface or an extension of the solid surface with an agent which has functional groups which react with the solid surface and the crosslinked polyalkyleneimine. For example, when the medical article has a polymeric surface, a thin but densely formed hydrogel graft polymer can be applied by providing a base layer of grafted acrylamide on the polymeric surface which can be used to attach the crosslinked polyalkyleneimine spacer. Such an acrylamide layer can be provided as set forth in our U.S. Patent 5,229,172, which is incorporated herein by reference. Or, when the medical article has a metal or glass surface, the coating can include a silane compound having a vinyl

functionality such that the silane adheres to the surface with the vinyl functionality pendant from the surface and then forming a graft polymer on the surface with applied silane such that the pendant vinyl functionality of the silane is incorporated into the graft polymer by covalently bonding it to the graft polymer. Or, alternatively, the crosslinked polyalkyleneimine can be the top layer (or also in the intermediate layers) in an ionically bonded complex as taught by U. S. Patent 4,565,740 to Golander et al. or U.S. Patent 5,049,403 to Larm et al.

The crosslinked polyalkyleneimine spacer of the present invention is used to attach heparin or other biomolecules to a solid surface. The biomolecule can be essentially any biomolecule which is attached to the solid surfaces of biomaterials to improve biocompatibility of the biomaterial. The biomolecule may be a growth factor such as endothelial cell growth factor, epithelial cell growth factor, osteoblast growth factor, fibroblast growth factor, platelet derived growth factor, neural growth factor, or angiogenic growth factor; an antimicrobial agent such as lysozyme or polymixin; an antithrombogenic agent such as heparin, fractionated heparins (e.g., on an AT-III column), heparan, heparan sulfate, chondroitin sulfate, modified dextran, albumin, streptokinase, tissue plasminogen activator (TPA) or urokinase; cell attachment proteins such as fibronectin or laminin; a thrombogenic agent such as collagen or a hydrophilic polymer such as hyaluronic acid, chitosan or methyl cellulose, and other proteins, carbohydrates and fatty acids. In a preferred embodiment, the biomolecule is heparin which has been modified to include an aldehyde group which is capable of reacting with one of the amine groups of the crosslinked polyalkyleneimine to covalently bond the heparin to the spacer.

The following examples provide specific embodiments of the invention.

#### Example 1

A piece of coiled tantalum wire was ultrasonically cleaned in 2% Micro-clean for 30 minutes followed by ultrasonic treatment in deionized water for 30 minutes. This last step was repeated after which the coil was rinsed in isopropanol and dried at 50°C for 20 minutes.

The cleaned coil was swirled in a 2% solution of trichlorovinylsilane (Merck Darmstadt, FRG) in xylene for 60 seconds followed by rinsing for 60 seconds in xylene, 60 seconds in isopropanol, 60 seconds in water and finally in acetone. The coil was then allowed to air dry overnight.

5           The dried coil was then placed into a glass tube which was filled with 15 ml of an aqueous solution of 35 wt% of freshly distilled acrylic acid and 5 wt % acrylamide. To the 15 ml of monomer solution, 0.9 ml of a solution of ceric ammonium nitrate (0.1M) in nitric acid (0.1M) was added. Deaeration was performed for 3-5 minutes at about 18 mm Hg followed by ultrasonic treatment for 10 minutes and an additional  
10 incubation of 35-40 minutes, all at room temperature. The grafted samples were then rinsed 10 times with deionized water at 50°C followed by an overnight incubation at 50°C. Samples taken showed a deep stain when soaked in toluidine blue solution.

          An aqueous solution of polyethyleneimine (PEI) (Polymin from BASF Mw=60,000) at a concentration of 0.05 wt% PEI was prepared in a 0.1M borate  
15 buffer pH=9.2. 100 mmol of divinyl sulfone was added to the solution per 0.5 gram PEI and allowed to react overnight. The coil was then incubated in the crosslinked PEI solution for one hour while shaking. After rinsing with deionized water, water soluble carbodiimide (1-(3-diethylaminopropyl)-3-ethylcarbodiimide.HCl) at a concentration of 0.05M was added. Coupling of the PEI spacer was allowed to  
20 proceed for one hour while shaking followed by rinsing with deionized water for 10 minutes.

          Oxidized heparin was prepared by adding 0.165 mg NaIO<sub>4</sub>/ml to 5 mg native heparin (Akzo)/ml 0.05M phosphate buffer (pH=6.88; 0.025M K<sub>2</sub>HPO<sub>4</sub> + NaH<sub>2</sub>PO<sub>4</sub>\*2H<sub>2</sub>O). After overnight oxidation under the exclusion of light, the resulting  
25 heparin solution was diluted in 0.4M acetate pH=4.6 at a ratio of 1:20. 0.1 mg of NaCNBH<sub>3</sub> /ml was added to the diluted heparin and the coil was incubated in this solution for 2 hours at 50°C. After rinsing with deionized water, 1M NaCl and water again to remove loosely bonded heparin, the coil was incubated with toluidine blue which provided an even lilac stain, indicating successful heparinization. An additional  
30 bioactivity test was also successfully performed to determine the ability of the

heparinized surface to deactivate thrombin via activation of previously adsorbed antithrombin III.

5 It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited and that numerous other embodiments, examples, uses, modifications and departures from the embodiments, examples and uses may be made without departing from the inventive concepts.


## CLAIMS:

1. A medical device having a solid surface for contact with blood or tissue of a patient, the surface provided with a spacer material attaching a biomolecule to the solid surface comprising:


- 5 (a) a polyalkyleneimine attached to the solid surface, the polyalkyleneimine crosslinked with a crosslinking agent which is at least difunctional in vinyl groups, each of said vinyl groups adjacent to a strong electron-withdrawing group; and
- (b) a biomolecule covalently bonded to amine functionalities of the crosslinked polyalkyleneimine.

10 2. The medical device according to claim 1 wherein the polyalkyleneimine is polyethyleneimine.

3. The medical device according to claim 1 or 2 wherein the crosslinking agent has the structure



15 where A is selected from the group consisting of



20 and



25 where R is a C<sub>1</sub> to C<sub>10</sub> alkyl group.

4. A method for making a medical device having a solid surface for contacting blood or tissue of a patient, the solid surface having applied thereto a spacer and an immobilized biomolecule by the steps of:

- 30 (a) reacting a polyalkyleneimine with a crosslinking agent which is at least difunctional in polymerizable vinyl groups, each of said polymerizable vinyl groups adjacent a strong electron-withdrawing group;

- (b) applying the reacted polyalkyleneimine to the solid surface; and
- (c) applying a biomolecule having a pendant aldehyde group to the applied polyalkyleneimine such that the pendant aldehyde group of the biomolecule covalently bonds to an amine functionality of the crosslinked polyalkyleneimine.

5           5. The method according to claim 4 wherein the polyalkyleneimine is polyethyleneimine.

6. The method according to claim 4 or 5 wherein the reaction between polyalkyleneimine and crosslinking agent takes place at alkaline pH with a crosslinking agent having the structure



where A is selected from the group consisting of



and



where R is a  $\text{C}_1$  to  $\text{C}_{10}$  alkyl group.

25           7. A medical device having a solid surface for contact with blood of a patient, the surface provided with a spacer material attaching heparin to the solid surface comprising:


30           (a) a polyethyleneimine attached to the solid surface, the polyethyleneimine crosslinked with a crosslinking agent which is at least difunctional in polymerizable vinyl groups, each of said polymerizable vinyl groups adjacent a strong electron-withdrawing group selected from the group consisting of sulfone, carbonyl, azo, sulfamido and nitro groups; and

(b) heparin covalently bonded to amine functionalities of the crosslinked polyethyleneimine.


8. The medical device according to claim 7 wherein the crosslinking agent has the structure



where A is selected from the group consisting of



and



where R is a C<sub>1</sub> to C<sub>10</sub> alkyl group.

9. A method for making a medical device having a solid surface for contacting blood of a patient, the solid surface having applied thereto a spacer and immobilized heparin by the steps of:


(a) reacting a polyalkyleneimine with a crosslinking agent which is at least difunctional in polymerizable vinyl groups, each of said polymerizable vinyl groups adjacent a strong electron-withdrawing group selected from the group consisting of sulfone, carbonyl, azo, sulfamido and nitro groups;

(b) applying the reacted polyalkyleneimine to the solid surface;

(c) treating heparin to produce a pendant aldehyde group on the heparin; and


(d) applying the treated heparin to the applied polyalkyleneimine such that the pendant aldehyde group of the heparin covalently bonds to an amine functionality of the crosslinked polyalkyleneimine.

10. The method according to claim 9 wherein the reaction between polyalkyleneimine and crosslinking agent takes place at alkaline pH with a crosslinking agent having the structure




where A is selected from the group consisting of

5



and

10



where R is a C<sub>1</sub> to C<sub>10</sub> alkyl group.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/14274

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61L33/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	US 5 583 213 A (YAFUSO MASAO ET AL) 10 December 1996 see column 1, line 4 - line 11 see column 4, line 15 - line 40 -----	1-3,7-10

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&\* document member of the same patent family

Date of the actual completion of the international search

29 April 1997

Date of mailing of the international search report

22.05.1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Cousins-Van Steen, G

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCI/US 96/14274

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5583213 A	10-12-96	AU 5670996 A WO 9635722 A	29-11-96 14-11-96
-----			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**